Timothy G. Majors
100 IP cases indexed. Covers patent matters.
Cases Presided Over
100 cases indexed | Page 1 of 4
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Court decision.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted inter partes review of Inari Medical’s 11,974,910 clot‑treatment patent after Imperative Care showed a reasonable likelihood of success on multiple obviousness grounds.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s embolism‑treatment patent after finding Imperative Care’s obviousness arguments sufficiently persuasive. All 36 challenged claims are now under review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care seeks to invalidate nine claims of Inari Medical’s 11,697,012 hemostasis valve patent. The PTAB instituted the IPR, finding a reasonable likelihood of unpatentability based on multiple prior‑art references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 patent covering intravascular embolism treatment devices after finding Imperative Care’s likelihood of success on at least one claim. The decision centers on claim constructions of the “filament” element and obviousness over multiple prior‑art references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care secured an institution of inter partes review against Inari Medical’s hemostasis valve patent covering claims 1‑9. The Board found a reasonable likelihood of unpatentability based on anticipation and obviousness grounds involving Schaffer, Hartley, and Eller references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,844,921 B2 hemostasis valve patent after Imperative Care showed a reasonable likelihood of success on multiple claims. The dispute centers on the definition of “filament” and reliance on prior art Schaffer, Hartley, and Eller.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an IPR on Inari Medical’s 11,697,012 patent covering hemostasis valves for aspiration catheters after finding a reasonable likelihood that Imperative Care will prevail on at least one of the nine challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care challenged Inari Medical’s 11,844,921 B2 hemostasis valve patent. The PTAB found a reasonable likelihood of unpatentability and instituted inter partes review on all 18 challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 B2 catheter aspiration patent after Imperative Care showed a reasonable likelihood of success on at least one claim. The review covers all 15 claims and four obviousness grounds involving Garrison, Schaffer, Hartley, and Eller references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,974,910 patent after finding Imperative Care likely to succeed on at least one claim, focusing on obviousness over Garrison, Laub, and Aklog references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success on at least one claim.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care successfully instituted an IPR against Inari Medical's 11,969,333 B2 patent covering intravascular clot removal. The Board found a reasonable likelihood of unpatentability based on obviousness over Laub, Garrison, and related references, and instituted review on all 36 challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent after Imperative Care showed a reasonable likelihood of success, focusing on the definition of “filament” and its flexibility versus prior art.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable, finding anticipation and obviousness over Schaffer, Hartley, Eller and Garrison references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted institution of an IPR on Inari Medical’s 12,109,384 patent covering hemostasis valves. All nine claims are under review based on anticipation and obviousness arguments centered on the Schaffer reference and related prior art.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted institution of an IPR against Inari Medical’s 11,969,333 patent covering intravascular clot‑removal systems. Petitioner Imperative Care showed a reasonable likelihood of success on at least one claim, prompting the Board to institute review on all challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success on at least one claim.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,865,291 B2 hemostasis valve patent after Imperative Care showed a reasonable likelihood of success. All 16 challenged claims are now subject to trial.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s 11,974,910 patent covering clot‑removal systems. Imperative Care successfully demonstrated a reasonable likelihood of unpatentability on multiple claims, prompting full‑scale review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,844,921 B2 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success on at least one claim. The dispute centers on the definition of “filament” and the applicability of Schaffer, Hartley, and Eller references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted inter partes review on all fifteen claims of Inari Medical’s ’005 patent, finding Imperative Care’s obviousness arguments against the hemostasis valve features sufficiently plausible.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that Imperative Care’s challenge to Inari Medical’s hemostasis valve patent succeeded, finding all nine claims unpatentable under §§ 102 and 103 based on prior‑art references Schaffer, Hartley, Eller, and Garrison.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted inter partes review of Inari Medical’s 11,844,921 B2 hemostasis valve patent after finding Imperative Care has shown a reasonable likelihood of success on at least one claim. The dispute centers on whether the claimed “filament” must be flexible, with the Board presently favoring the patent owner’s interpretation.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 B2 embolism‑treatment patent after finding Imperative Care likely to prevail on at least one claim. All 15 claims are now under review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care’s petition to invalidate Inari Medical’s hemostasis valve patent was granted. The Board found a reasonable likelihood of success on anticipation and obviousness grounds and instituted review of all nine claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent (U.S. Patent 11,697,012) on all nine claims after finding the challenger, Imperative Care, showed a reasonable likelihood of prevailing. The dispute centers on claim construction of “filament” and alleged anticipation/obviousness over prior‑art references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis valve patent are unpatentable. The Board’s claim construction of “filament” as a flexible element undermined the anticipation argument and found the obviousness combinations persuasive.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care successfully challenged the patentability of Inari Medical's hemostasis valve claims before the PTAB, leading to institution on grounds of anticipation and obviousness. The Board focused heavily on claim construction, ultimately defining 'filament' as a flexible length of material necessary for the device function. This decision sets important precedent regarding functional limitations in medical device patents.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable, finding anticipation and obviousness over Schaffer and its combinations with Hartley, Eller, and Garrison.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.